Molecularly targeted therapies for acute myeloid leukemia

Hematology Am Soc Hematol Educ Program. 2015:2015:579-83. doi: 10.1182/asheducation-2015.1.579.

Abstract

The past 15 years have seen major leaps in our understanding of the molecular genetic mutations that act as drivers of acute myeloid leukemia (AML). Clinical trials of agents against specific mutant proteins, such as FLT3-internal tandem duplications (ITDs) and isocitrate dehydrogenase mutations (IDHs) are ongoing. This review discusses agents in clinical trials that target specific gene mutations and/or epigenetic targets.

Publication types

  • Review

MeSH terms

  • Aniline Compounds / therapeutic use
  • Antineoplastic Agents / therapeutic use
  • Benzimidazoles / therapeutic use
  • Benzothiazoles / therapeutic use
  • Clinical Trials as Topic
  • Epigenesis, Genetic
  • Humans
  • Isocitrate Dehydrogenase / metabolism
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / genetics
  • Molecular Targeted Therapy*
  • Mutation
  • Phenylurea Compounds / therapeutic use
  • Piperidines / therapeutic use
  • Proto-Oncogene Proteins c-bcl-2 / antagonists & inhibitors
  • Pyrazines / therapeutic use
  • fms-Like Tyrosine Kinase 3 / genetics

Substances

  • Aniline Compounds
  • Antineoplastic Agents
  • Benzimidazoles
  • Benzothiazoles
  • Phenylurea Compounds
  • Piperidines
  • Proto-Oncogene Proteins c-bcl-2
  • Pyrazines
  • gilteritinib
  • quizartinib
  • IDH2 protein, human
  • Isocitrate Dehydrogenase
  • IDH1 protein, human
  • FLT3 protein, human
  • fms-Like Tyrosine Kinase 3
  • crenolanib